First Trust Advisors
NBSE

First Trust Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

First Trust Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,655
Closed -$350K – 2666
2021
Q2 		$350K Buy
3,655
+972
+36% +$107K ﹤0.01% 2351
2021
Q1 		$397K Buy
2,683
+222
+9% +$40.2K ﹤0.01% 2277
2020
Q4 		$344K Sell
2,461
-112
-4% -$18.1K ﹤0.01% 2201
2020
Q3 		$391K Buy
+2,573
New +$420K ﹤0.01% 2106

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors's NBSE Position: Q3 2021 in Review

First Trust Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2021, closing a stake of 3,655 shares — an estimated $350K sold.

First Trust Advisors first reported a position in NBSE in Q3 2020 and held it in 4 quarters. The position peaked at $397K in Q1 2021. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2021.

  • First Trust Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • First Trust Advisors sold 3,655 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $350K.
  • First Trust Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • First Trust Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $397K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2021.

Based on First Trust Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.